bpc-157 oral vs injectable research Oral vs. injectable bpc157 :

Side effects are rare but may include redness or swelling at the injection site, and occasional nausea

Lots subject to the recall include Sermorelin / Ipamorelin 3mg Lot# SIP210

The table below shows where each one fits

The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners